GKO Stock Overview A biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
GlycoMimetics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for GlycoMimetics Historical stock prices Current Share Price US$0.22 52 Week High US$3.19 52 Week Low US$0.13 Beta 1.78 1 Month Change -17.82% 3 Month Change 47.57% 1 Year Change -90.09% 3 Year Change -82.76% 5 Year Change -95.22% Change since IPO -96.83%
Recent News & Updates Crescent Biopharma, Inc. entered into an acquisition agreement to acquire GlycoMimetics, Inc. (NasdaqGM:GLYC) in a reverse merger transaction. Oct 30
GlycoMimetics, Inc. Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint Oct 29
Insufficient new directors Oct 25 Glycomimetics Announces to Reduce Its Workforce by Approximately 80% Jul 26
GlycoMimetics Receives Non-Compliance letter from Nasdaq Regarding Listing Rule 5450(a)(1) Jun 27
Senior VP & Chief Medical Officer recently bought €74k worth of stock Jun 25 See more updates Crescent Biopharma, Inc. entered into an acquisition agreement to acquire GlycoMimetics, Inc. (NasdaqGM:GLYC) in a reverse merger transaction. Oct 30
GlycoMimetics, Inc. Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint Oct 29
Insufficient new directors Oct 25 Glycomimetics Announces to Reduce Its Workforce by Approximately 80% Jul 26
GlycoMimetics Receives Non-Compliance letter from Nasdaq Regarding Listing Rule 5450(a)(1) Jun 27
Senior VP & Chief Medical Officer recently bought €74k worth of stock Jun 25
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Jun 05
New major risk - Financial position May 13
New major risk - Revenue and earnings growth May 08
New minor risk - Profitability May 06
No longer forecast to breakeven May 06
GlycoMimetics, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 27
GlycoMimetics, Inc., Annual General Meeting, May 01, 2024 Apr 02
New minor risk - Profitability Mar 27
GlycoMimetics, Inc. to Report Q4, 2023 Results on Mar 27, 2024 Mar 14
GlycoMimetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023 Oct 21
New minor risk - Share price stability Oct 05
Senior VP & Chief Medical Officer recently bought €85k worth of stock Sep 26
GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 Sep 07
New minor risk - Market cap size Aug 17
GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia Jun 16
No longer forecast to breakeven Mar 31
Full year 2022 earnings released: US$0.89 loss per share (vs US$1.23 loss in FY 2021) Mar 30
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee Feb 16
Forecast to breakeven in 2025 Dec 31
Chief Medical Officer recently bought €234k worth of stock Dec 29
GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting Dec 13
Insufficient new directors Nov 16
Third quarter 2022 earnings released: EPS: US$0 (vs US$0.34 loss in 3Q 2021) Nov 10
GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer Sep 07
Second quarter 2022 earnings released: US$0.25 loss per share (vs US$0.28 loss in 2Q 2021) Aug 04
GlycoMimetics, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 28
GlycoMimetics Receives a Notice from Nasdaq Regarding Minimum Bid Price Requirement Jun 04
First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2021) Apr 29
Insufficient new directors Apr 27
GlycoMimetics, Inc. to Report Q1, 2022 Results on Apr 28, 2022 Apr 26
GlycoMimetics, Inc., Annual General Meeting, May 18, 2022 Apr 12
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 04
GlycoMimetics, Inc. to Report Q4, 2021 Results on Mar 03, 2022 Feb 26
GlycoMimetics, Inc. Appoints Bruce Johnson as Senior Vice President and Chief Commercial Officer Feb 24
Insufficient new directors Jan 01
Insufficient new directors Dec 06
Independent Director recently bought €72k worth of stock Nov 19
GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD Sep 24
Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients Jul 23
GlycoMimetics, Inc. Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination with Venetoclax and Azacitidine Jul 14 GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 3000E Value Index
GlycoMimetics, Inc. Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation May 27
First quarter 2021 earnings released: US$0.28 loss per share (vs US$0.18 loss in 1Q 2020) May 05
Senior VP of Clinical Development & Chief Medical Officer has left the company Mar 23
Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML Mar 05
Revenue beats expectations Mar 05
New 90-day low: €2.82 Feb 25 GlycoMimetics, Inc. Announces Resignation of Helen Thackray as Senior Vice President and Chief Medical Officer
New 90-day high: €3.42 Dec 24
GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition Nov 06
GlycoMimetics, Inc. to Report Q3, 2020 Results on Nov 06, 2020 Nov 01
New 90-day low: €2.50 Oct 30
GlycoMimetics, Inc. Presents New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 Reset Trial at the Annual Scientific Conference on Sickle Cell and Thalassemia Meeting Oct 27
FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease Oct 06
New 90-day low: €2.64 Sep 30 GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 2500 Growth Index Shareholder Returns GKO DE Biotechs DE Market 7D 4.0% 1.2% -0.3% 1Y -90.1% -14.3% 7.0%
See full shareholder returns
Return vs Market: GKO underperformed the German Market which returned 7% over the past year.
Price Volatility Is GKO's price volatile compared to industry and market? GKO volatility GKO Average Weekly Movement 46.6% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: GKO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: GKO's weekly volatility has increased from 28% to 47% over the past year.
About the Company GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein.
Show more GlycoMimetics, Inc. Fundamentals Summary How do GlycoMimetics's earnings and revenue compare to its market cap? GKO fundamental statistics Market cap €14.99m Earnings (TTM ) -€38.18m Revenue (TTM ) €9.61k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GKO income statement (TTM ) Revenue US$10.00k Cost of Revenue US$0 Gross Profit US$10.00k Other Expenses US$39.75m Earnings -US$39.74m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.62 Gross Margin 100.00% Net Profit Margin -397,350.46% Debt/Equity Ratio 0%
How did GKO perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 15:13 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources GlycoMimetics, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ying Huang Barclays John Newman Canaccord Genuity Naureen Quibria Capital One Securities, Inc.
Show 6 more analysts 
